Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
Key claim: A phase I study is evaluating the safety, tolerability, maximum tolerated dose, and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory AML or CMML.
Abstract
The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).
Why this matters
CMML patients with relapsed/refractory disease have few effective options, and the subtype is increasingly being included in first-in-human AML trials as a biologically related myeloid population. Tracking these early-phase entries (NMS-03592088, STX-0712, and others) on the CMML page helps map the emerging investigational landscape specific to this MDS/MPN overlap entity, even when mechanism is not yet disclosed.